Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20529016 | 0.80 | AMY1A (0.52) | AMY1AALDH1A1GAAGFERBACE1 | |
| SCHEMBL29695575 | 0.80 | AMY1A (0.52) | AMY1AALDH1A1GAAGFERBACE1 | |
| SCHEMBL20529090 | 0.76 | AMY1A (0.49) | AMY1AALDH1A1GAABACE1MPO | |
| SCHEMBL20529012 | 0.76 | AMY1A (0.49) | AMY1AALDH1A1GAABACE1MPO | |
| SCHEMBL29695498 | 0.76 | AMY1A (0.49) | AMY1AALDH1A1GAAGFERBACE1 | |
| SCHEMBL20529156 | 0.76 | AMY1A (0.49) | AMY1AALDH1A1GAAGFERBACE1 | |
| SCHEMBL20529052 | 0.75 | AMY1A (0.56) | AMY1AALDH1A1GAAGFERBACE1 | |
| SCHEMBL20529230 | 0.74 | AMY1A (0.47) | AMY1AALDH1A1GAABACE1MPO | |
| SCHEMBL28354031 | 0.74 | AMY1A (0.52) | AMY1AALDH1A1GAAGFERBACE1 | |
| SCHEMBL20529065 | 0.73 | AMY1A (0.46) | AMY1AALDH1A1GAABACE1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | INVENTIVA (FR) | 2020-04-16 | — | — | US | disclosed |
| EP-3606921-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | Inventiva (FR) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185266-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | YAP1, TEAD2, TEAD1 | AMY1A 4675/4885ALDH1A1 3397/4885GAA 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.